Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Second quarter (April-June 2023) · Operating profit/loss totaled SEK -4,466,286 (-3,641,800). · Loss for the period totaled SEK -4,335,852 (-3,667,200). · Cash flow from operating activities totaled SEK -2,146,178 (-3,877,975). · Earnings per share before dilution totaled SEK -0.22 (-0.19). Earnings per share after dilution amounted to SEK - 0.22 (-0.19). Period (January-June 2023) · Operating profit/loss totaled SEK -6,732,143 (-8,382,851). · Loss for the period totaled SEK -6,602,181 (-8,421,815). · Cash flow from operating activities totaled SEK -4,181,